Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy

Drug Des Devel Ther. 2017 Apr 11:11:1175-1182. doi: 10.2147/DDDT.S110209. eCollection 2017.

Abstract

Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 clinical trials of nivolumab in mRCC.

Keywords: PD-1; immunotherapy; kidney cancer; nivolumab; renal cell carcinoma.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / immunology
  • Clinical Trials as Topic
  • Drug Design*
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / immunology
  • Nivolumab

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Nivolumab